Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of Company Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $33.64, for a total value of $110,608.32. Following the completion of the transaction, the insider owned 48,719 shares of the company’s stock, valued at $1,638,907.16. This trade represents a 6.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Shares of CSTL opened at $33.11 on Thursday. The stock has a 50-day moving average of $33.50 and a two-hundred day moving average of $26.74. Castle Biosciences, Inc. has a one year low of $17.72 and a one year high of $44.28. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.34. The business had revenue of $99.86 million for the quarter, compared to the consensus estimate of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. On average, research analysts forecast that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in Castle Biosciences during the second quarter worth about $78,513,000. Summit Partners Public Asset Management LLC lifted its holdings in Castle Biosciences by 164.7% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after acquiring an additional 658,725 shares during the period. Jefferies Financial Group Inc. acquired a new position in Castle Biosciences in the second quarter valued at approximately $15,440,000. Renaissance Technologies LLC lifted its holdings in Castle Biosciences by 8.1% in the first quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock valued at $13,080,000 after acquiring an additional 39,700 shares during the period. Finally, AIGH Capital Management LLC purchased a new stake in Castle Biosciences in the 2nd quarter worth approximately $13,001,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Castle Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 26th. Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Roth Capital started coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price target for the company. BTIG Research raised their price target on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Castle Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious diseases. Its products analyze biological characteristics in tissue samples to help physicians assess disease risk, guide treatment decisions and support patient management.

The company’s portfolio includes diagnostic tests for skin cancers, such as DecisionDx-Melanoma for assessing metastatic risk in patients with cutaneous melanoma and DecisionDx-SCC for evaluating metastatic risk in certain cases of cutaneous squamous cell carcinoma.